Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Doyle, Lex W ^a   Crowther, Caroline A ^b   Middleton, Philippa ^b   Marret, Stephane ^c   Rouse, Dwight ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

*Premature birth; Central nervous system diseases *prevention control ; Cerebral palsy mortality; prevention control ; Female; Fetal death *prevention control ; Humans; Infant, newborn; Magnesium sulfate *therapeutic use ; Neuroprotective agents *therapeutic use ; Pregnancy; Prenatal care; Randomized controlled trials as topic

Indexed keywords

MAGNESIUM SULFATE; PLACEBO;

APGAR SCORE; ASSISTED VENTILATION; BABY; BENIGN CHILDHOOD EPILEPSY; BLINDNESS; BRAIN HEMORRHAGE; CEREBRAL PALSY; CESAREAN SECTION; CHILD; CHILDBIRTH; CHILDHOOD MORTALITY; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COGNITION; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG SAFETY; ENCEPHALOMALACIA; FETUS; FETUS DEATH; GESTATIONAL AGE; HEARING IMPAIRMENT; HEART ARREST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOTENSION; INFANTILE HYPOTONIA; INTENSIVE CARE UNIT; LIVE BIRTH; LOADING DRUG DOSE; MATERNAL MORTALITY; MORTALITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NEUROPROTECTION; OUTCOME ASSESSMENT; PEDIATRICS; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRENATAL CARE; RESPIRATION DEPRESSION; RESPIRATORY ARREST; RETREATMENT; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 65849208118     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004661.pub3     Document Type: Review

References (85)

1. Crowther CA, Hiller JE, Doyle LW, Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgS)4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA 2003;290(20):2669-2676
2. Crowther CA, Hiller JE, Doyle LW, Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290(20):2669-2676
3. Crowther CA, Hiller JE, Doyle LW for the ACTOMgSO4 Collaborators Group. Does prenatal magnesium sulphate reduce the risk of mortality and cerebral palsy in infants born at less than 30 weeks' gestation? - The ACTOMgS04 trial. Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:A4.
4. Paradisis M, Evans N, Osborn D, Kluckow M, ACTOMgSO4 Collaborators Group. The effect of antenatal magnesium sulphate on early systemic blood flow in very preterm infants. Pediatric Research 2004;55 Suppl:114.
5. Smith CA, Crowther CA, Willson K, Hiller JE, Doyle LW. Placental transfer of magnesium sulphate: a randomised placebo controlled trial. Perinatal Society of Australia and New Zealand 7th Annual Congress; 2003 March 9-12; Tasmania, Australia. 2003:P48.
6. Magpie Trial Follow Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG: an international journal of obstetrics and gynaecology 2007;114 (3):289-299
7. Marret S, Marpeau L, Astruc D, Cambonie G, Follet C, Benichou J. Prenatal magnesium sulfate (MgSO4) and follow up at two years of age in preterm infants: the randomised controlled PREMAG trial. Pediatric Academic Societies Annual Meeting; 2007 May 5-8; Toronto, Canada. 2007.
8. Marret S, Marpeau L, Benichou J. Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics 2008; 121(1):225-226
9. Marret S, Marpeau L, Follet-Bouhamed C, Cambonie G, Astruc D, Delaporte B, et al. for the PREMAG Group. Effect of magnesium sulphate on mortality and neurologic morbidity of the very=preterm newborn with two-year neurological outcome: results of the prospective PREMAG trial [Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul è deux ans: résultats de l'essai prospectif multicentrique contre placebo PREMAG]. Gynécologie Obstétrique & Fertilité 2008;36:278-288
10. * Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, et al. Magnesium sulfate given before very-preterm birth to protect infant brain: the randomized, controlled PREMAG trial. BJOG: an international journal of obstetrics and gynaecology 2007; Vol.114, issue 3:310-318
11. Marret S, Zupan V, Marpeau L, Adde-Michel C, Benichou J, the Premag Trial Group. Prenatal magnesium sulphate (MgSO4) and neuroprotection in preterm infants: a randomized controlled trial. Pediatric Academic Societies Annual Meeting; 2005 May 14-17; Washington DC, USA. 2005.
12. Mittendorf R, Bentz L, Borg M, Roizen N. Does exposure to antenatal magnesium sulfate prevent cerebral palsy?. American Journal of Obstetrics and Gynecology 2000;182(1 Pt 2):S20.
13. Mittendorf R, Bentz L, Kohn J, Covert R. Use of antenatal magnesium sulfate does not seem to prevent intraventricular hemorrhage. American Journal of Obstetrics and Gynecology 2000;182(1 Pt 2):S34.
14. Mittendorf R, Besinger R, Santillan M, Gianopoulos J. When used in circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MGSO4) on the developing human brain?. American Journal of Obstetrics and Gynecology 2005;193(6 Suppl):S65.
15. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality?. Lancet 1997;350(9090):1517-1518 (Pubitemid 28036557)
16. Mittendorf R, Covert R, Elin R, Pryde P, Khoshnood B, Sun-Lee K. Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstetrics & Gynecology 2001;98:75-78 (Pubitemid 32622767)
17. Mittendorf R, Dambrosia J, Dammann O, Pryde PG, Lee KS, Ben-Ami TE, et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. Journal of Pediatrics 2002;140(5):540-546 (Pubitemid 34666723)
18. Mittendorf R, Dambrosia J, Khoshnood B, Lee KS, Pryde P, Yousefzadeh D. Association between magnesium and intraventricular haemorrhage. American Journal of Obstetrics and Gynecology 2001; 184(1):S188.
19. Mittendorf R, Dambrosia J, Khoshnood B, Lee K-S, Pryde P, Yousefzadeh D. Magnesium sulfate is no more efficacious than other tocolytic agents. American Journal of Obstetrics and Gynecology 2001; 184(1):S188.
20. * Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology 2002;186(6):1111-1118
21. Mittendorf R, Janeczek S, Macmillan W, Gianopoulos J, Besinger R, Karlman R, et al. Mechanisms of mortality in the magnesium and neurologic endpoints trial (magnet trial): fetal inflammatory response syndrome (firs). American Journal of Obstetrics and Gynecology 2001;185(6 Suppl):S151.
22. Mittendorf R, Kuban K, Pryde PG, Gianopoulos JG, Yousefzadeh D. Antenatal risk factors associated with the development of lenticulostriate vasculopathy (lsv) in neonates. Journal of Perinatology 2005; 25(2):101-107 (Pubitemid 40277381)
23. Mittendorf R, Pryde P, Khoshnood B, Lee KS. If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?. Obstetrics & Gynecology 1998;92(2):308-311 (Pubitemid 28350870)
24. Mittendorf R, Pryde P, Lee KS, Besinger R, Macmillan W, Karlman R, et al. Umbilical cord serum ionized magnesium levels at delivery are not correlated with neuroprotection in childhood. American Journal of Obstetrics and Gynecology 2002;187(6 Pt 2):S74.
25. Mittendorf R, Pryde P, Lee K-S, Besinger R, MacMillan W, Karlman R, et al. Coagulase negative staphylococci cultured from the placental chorioamnion space at delivery are associated with lower bayley scores. American Journal of Obstetrics and Gynecology 2002;187(6 Pt 2):S131.
26. Santillan M, Besinger RE, Gianopoulos JG, Mittendorf R. An inverse correlation between umbilical cord blood ionizedmagnesium(IMG) and interleukin-6 (IL-6) levels could not be confirmed in the human. American Journal of Obstetrics and Gynecology 2005;193(6 Suppl): S183.
27. NICHD. Beneficial effects of antenatal magnesium sulfate. Clinical Trials. gov (http://clinicaltrials.gov/) (accessed 11 January 2007). Rouse D. 1: A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. American journal of obstetrics and gynecology (0002-9378) 2007;197(6):S2. [DOI: 10.1016/j.ajog.2007.10.002]
28. * Rouse D, Hirtz D, Thom E, Varner M, Alexander J, Spong C, Mercer B, Iams J, Wapner R, Sorokin Y, Harper M, Thorp J, Ramin S, Malone F, Carpenter M, Miodovnik A, Moawad A, O'Sullivan M, Peaceman A, Hankins G, Langer O, Caritis S, Roberts J. Magnesium sulfate for the prevention of cerebral palsy. New England Journal of Medicine 2008;359:895-905.
29. Amiel-Tison C, Gosselin J, eds. Démarche clinique en Neurologie du développement. Paris: Masson, 2004.
30. Bayley N. Bayley Scales of Infant Development. San Antonio, TX: The Psychological Corporation, 1969.
31. Bayley N. Bayley Scales of Infant Development. Second Edition. San Antonio, TX: The Psychological Corporation, 1993.
32. Blasco PA. Primitive reflexes: their contribution to the early detection of cerebral palsy. Clinical Pediatrics 1994;33:388-397
33. Canterino JC, Verma UL, Visintainer PF, Figueroa R, Klein SA, Tejani NA. Maternal magnesium sulfate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. Obstetrics & Gynecology 1999;93:396-402.
34. Capute AJ, Shapiro BK. The motor quotient: a method for the early detection of motor delay.. American Journal of Diseases of Children 1985;139:940-942
35. Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database of Systematic Reviews 1998, Issue 1. [DOI: 10.1002/14651858.CD000940]
36. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD001060]
37. Doyle LW, for the Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the prognosis. Pediatrics 2001;108(1):134-141
38. Drummond PM, Colver AF. Analysis by gestational age of cerebral palsy in singleton births in north-east England 1970-94. Paediatric and Perinatal Epidemiology 2002;16:172-180
39. Duley L, Gulmezoglu AM. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002960]
40. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD000127]
41. Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD000128]
42. Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000025]
43. Espinoza MI, Parer JT. Mechanisms of asphyxial brain damage, and possible pharmacologic interventions, in the fetus. American Journal of Obstetrics and Gynecology 1991;164(6 Pt 1):1582-1589
44. Finesmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, et al. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. American Journal of Perinatology 1997;14(5):303-307
45. Grether JK, Hoogstrate J, Selvin S, Nelson KB. Magnesium sulfate tocolysis and risk of neonatal death. American Journal of Obstetrics and Gynecology 1998;178(1 Pt 1):1-6.
46. Grether JK, Hoogstrate J, Walsh-Greene E, Nelson KB. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. American Journal of Obstetrics and Gynecology 2000;183(3):717-725
47. Hagberg B, Hagberg G, Beckung E, Uvebrant P. Changing panorama of cerebral palsy in Sweden. VIII. Prevalence and origin in the birthyear period 1991-94. Acta Paediatrica 2001;90:271-277
48. Hauth JC, Goldenberg RL, Nelson KG, DuBard MB, Peralta MA, Gaudier FL. Reduction of cerebral palsy with maternal MgSO4 treatment in newborns weighing 500-1000g [abstract]. American Journal of Obstetrics and Gynecology 1995;172(1 Pt 2):419.
49. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
50. Himmelmann K, Hagberg G, Beckung E, Hagberg B, Uvebrant P. The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995-1998. Acta Paediatrica 2005;94:287-294
51. Hutton JL, Cooke T, Pharoah TOD. Life expectancy in children with cerebral palsy. BMJ 1994;309:431-435
52. Kimberlin DF, Hauth JC, Goldenberg RL, Bottoms SF, Iams JD, Mercer B, et al.The effect of maternal magnesium sulfate treatment on neonatalmorbidity in < or = 1000-graminfants. American Journal of Perinatology 1998;15:635-641
53. Kuban KCK, Leviton A, Pagano M, Fenton T, Strasfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. Journal of Child Neurology 1992;7:70-76
54. Kuban K, Leviton A, Pagano M, Fenton T, Strasfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. Journal of Child Neurology 1992;7:70-76
55. Levene M, Blennow M, Whitelaw A, Hanko E, Fellman V, Hartley R. Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia. Archives of Disease in Childhood. Fetal Neonatal Edition 1995;73:F174-F177.
56. Lipsitz P. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics 1971;47:501-509
57. Lorenz JM, Wooliever DE, Jetton JR, Paneth N. Aquantitative review of mortality and developmental disability in extremely premature newborns. Archives of Pediatrics and Adolescent Medicine 1998;152: 425-435
58. Makrides M, Crowther CA. Magnesium supplementation in pregnancy. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000937]
59. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, et al.Births: final data for 2005. National Vital Statistics Reports 2007;56(6):1-103.
60. McDonald JW, Silverstein FS, Johnston MV. Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neuroscience Letters 1990;109:234-239
61. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 1995;95: 1-10.
62. O'Shea TM, Klinepeter KL, Meis PJ, Dillard RG. Intrauterine infection and the risk of cerebral palsy in very low-birthweight infants. Paediatric and Perinatal Epidemiology 1998;12(1):72-83.
63. Oxford Register of Early Childhood Impairments. National Perinatal Epidemiology Unit 2001 Annual Report. Oxford: Institute of Health Sciences, 2001.
64. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology 1997;39(4):214-223
65. Paneth N, Jetton J, Pinto-Martin J, Susser M. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemorrhage Study Analysis Group. Pediatrics 1997;99(5):E1.
66. Perlman J, Fermandez C, Gee J, LeVeno K, Risser R. Magnesium sulphate administered tomothers with pregnancy-induced hypertension is associated with a reduction in periventricular-intraventricular hemorrhage [abstract]. Pediatric Research 1994;37:231A.
67. Petterson B, Nelson KB, Watson L, Stanley F. Twins, triplets and cerebral palsy in births in Western Australian in the 1980s. BMJ 1993;307:1239-1243
68. Pharoah PO, Cooke T, Cooke RW, Rosenbloom L. Epidemiology of cerebral palsy in England and Scotland 1984-1989. Archives of Disease in Childhood. Fetal and Neonatal Edition 1998;79:F21-F25.
69. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
70. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996;276(22):1805-1810
71. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Developmental Medicine and Child Neurology 2000;42(12):816-824
72. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics & Gynecology 2003;102:181-192
73. Stanley FJ, Watson L. Trends in perinatal mortality and cerebral palsy in Western Australia, 1967 to 1985. BMJ 1992;304(6843):1658-1663
74. Stanley FJ. The aetiology of cerebral palsy. Early Human Development 1994;36:81-88
75. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Evaluation and the Health Professions 2002;25(1):76-97.
76. Surman G, Newdick H, Johnson A. Cerebral palsy rates among low-birthweight infants fell in the 1990s. Developmental Medicine and Child Neurology 2003;45:456-462
77. Vermeulen GM, Bruinse HW, de Vries LS. Perinatal risk factors for adverse neurodevelopmental outcome after spontaneous preterm birth. European Journal of Obstetrics & Gynecology and Reproductive Biology 2001;99:207-212
78. The Victorian Infant Collaborative Study Group. Outcome at 2 years of children 23-27 weeks' gestation born in Victoria in 1991-92. Journal of Paediatric Child Health 1997;33(2):161-165
79. Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O, et al. Effect ofmaternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 2001;85:F13-7.
80. Winter S, Autry A, Boyle C, Yeargin-Allsop M. Trends in the prevalence of cerebral palsy in a population-based study. Pediatrics 2002; 110:1220-1225
81. Wiswell TE, Graziani LJ, Caddell JL, Vecchione N, Stanley C, Spitzer AR. Maternally administered magnesium sulphate protects against early brain injury and long-term adverse neurodevelopmental outcomes in preterm infants. A prospective study. Pediatric Research 1996;39:253A.
82. Keirse M. Magnesium sulphate in preterm labour. [revised 07 April 1994]. Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration. Issue 2. Oxford: Update Software, 1995.
83. Keirse M. Magnesium sulphate and betamimetics for tocolysis in preterm labour [revised 07 April 1994]. Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2. Oxford: Update Software, 1995.
84. Keirse M. Magnesium sulphate vs betamimetics for tocolysis in preterm labour. [revised 07 April 1994]. Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2. Oxford: Update Software, 1995.
85. Keirse M. Magnesium sulphate vs ethanol for tocolysis in preterm labour. [revised 07 April 1994]. Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2. Oxford: Update Software, 1995.